# Cell competition in pulmonary fibrosis and ARDS

> **NIH NIH R35** · MAYO CLINIC ROCHESTER · 2022 · $954,000

## Abstract

Idiopathic pulmonary fibrosis (IPF) is a common form of interstitial lung disease (ILD), resulting in alveolar
remodeling and progressive loss of pulmonary function, respiratory failure, and death often within 5 years of
diagnosis. Genetic and experimental evidence support the concept that chronic alveolar epithelial injury and
failure to properly repair the respiratory epithelium are intrinsic to IPF disease pathogenesis. Histologically,
respiratory epithelial cells in the lung parenchyma are replaced by cells which are normally restricted to
conducting airways. Fibrotic lesions and honeycomb structures replace alveoli, the latter normally lined by
alveolar type 1 (AT1) and AT2 cells. Acute exacerbations by respiratory viral infections are the most devastating
complication of IPF, having an in-hospital mortality rate of greater than 50%. Data from previous coronavirus
pandemics such as severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS),
as well as emerging data from the COVID-19 pandemic, suggest there could be substantial fibrotic
consequences following SARS-CoV-2 infection, the causative agent of COVID-19. Interestingly, the major risk
factors for severe COVID-19 are shared with idiopathic pulmonary fibrosis (IPF), namely increasing age, male
sex, and comorbidities such as hypertension and diabetes. Although many patients who develop acute
respiratory distress syndrome (ARDS) survive the acute phase of the illness, a substantial proportion die as a
result of progressive pulmonary fibrosis. It remains unclear why certain individuals are able to recover from
ARDS, whereas in others there is a shift to unchecked cellular proliferation with the accumulation of BC-pods,
fibroblasts and myofibroblasts. In these patients, there is also excessive deposition of collagen alongside other
components of the extracellular matrix resulting in progressive pulmonary fibrosis. Distinct epithelial
stem/progenitor cell pools and/or their mesenchymal niches repopulate injured tissue depending on the extent
and type of injury, and the outcomes of regeneration or fibrosis in response to severe alveolar epithelial injury is
dependent in part on the dynamics of cell competition between these cell populations. In tissues harboring a
mosaic imbalance in cMyc or Yap protein levels, cells with higher cMyc or nuclear Yap levels become super-
competitors and expand at the expense of cells with lower levels, by eliminating them. Alternatively, if certain
stem cell populations are selectively wiped out due to the type of injury, other stem cell populations that escape
the injury and which may not be so adept at replacing the destroyed tissue will now have a competitive
advantage. For example, SARS-CoV-2 enters respiratory epithelial cells via its receptor, angiotensin-converting
enzyme 2 (ACE2), causing severe airway and alveolar epithelial injury. Based on Ace2 expression, distinct
stem/progenitor cell pools appear to be differentially susce...

## Key facts

- **NIH application ID:** 10350993
- **Project number:** 1R35HL161169-01
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** Stijn Piet Johan De Langhe
- **Activity code:** R35 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $954,000
- **Award type:** 1
- **Project period:** 2022-08-20 → 2029-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10350993

## Citation

> US National Institutes of Health, RePORTER application 10350993, Cell competition in pulmonary fibrosis and ARDS (1R35HL161169-01). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10350993. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*